CAMBRIDGE, Mass.--(BUSINESS WIRE)--ImmusanT, Inc., a company developing Nexvax2®, a therapeutic vaccine designed to protect against the effects of gluten exposure in HLA-DQ2.5+ patients with celiac disease, today announced two poster presentations and one oral presentation that will take place at Digestive Disease Week 2016, being held from Saturday, May 21 to Tuesday, May 24, 2016 at the San Diego Convention Center in San Diego, California. The company also announced that it will host a satellite symposium titled, “New Developments in Celiac Disease: The Promise of Disease-Modifying Immune Tolerance Therapy” on Sunday, May 22, 2016 at the Manchester Grand Hyatt Hotel in San Diego, California. The satellite symposium is not affiliated with Digestive Disease Week.
